



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary) <b>PTO FORM 1449</b>	ATTY. DOCKET NO. <b>05882.0183.NPUS00</b>	APPLICATION NO. <b>09/976,858</b>
	APPLICANT <b>Kurt C. Gish, <i>et al.</i></b>	
	FILING DATE <b>October 12, 2001</b>	GROUP <b>1642</b>

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DATE NO	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JS</i>	A1.	5,514,554	07/1995	Bacus			


FOREIGN PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>JS</i>	B1.	WO 98/18945	05/1998	PCT				
	B2.	WO 98/34118	08/1998	PCT				
	B3.	WO 99/23230	05/1999	PCT				
	B4.	WO 99/33869	07/1999	PCT				
	B6.	WO 99/25877	05/1999	PCT				
	B5.	WO 00/08210	02/2000	PCT				

OTHER REFERENCES			(Including Author, Title, Date, Pertinent Pages, Etc.)
<i>JS</i>	*	C1.	Ahn, <i>et al.</i> , "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> , 3(4):283-91 (1993)
	*	C2.	Cawthon, <i>et al.</i> , "cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene," <i>Genomics</i> 9(3):446-60 (1991)
	*	C3.	Oshima, <i>et al.</i> , Accession No: AK097748 7 (2002)
	*	C4.	Kibel, <i>et al.</i> "Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma," <i>J. Urol.</i> , 164(1): 192-6 (2000)
	*	C5.	MPSRCH search report, us-09-847-040-1.mg, pp. 6-7 <i>year?</i>
	*	C6.	Lewin, "Genes," John Wiley & Sons, New York, pp. 190-1 (1983)
	*	C7.	Mermod, "Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro," <i>Nature</i> 332(6164):557-61 (1988)
	**	C8.	Landis, <i>et al.</i> , "Cancer statistics 1998," <i>CA Cancer J. Clin.</i> 48(1):6-29 (1998)
	**	C9.	Greenlee, <i>et al.</i> , "Cancer statistics 2000," <i>CA Cancer J. Clin.</i> 50(1):7-33 (2000)
	**	C10.	Nakata, <i>et al.</i> , "Trends and characteristics in prostate cancer mortality in Japan," <i>Int. J. Urol.</i> 7(7):254-7 (2000)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

M. T. DAVIS

05/20/05



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

**PTO FORM 1449**

ATTY. DOCKET NO.

**05882.0183.NPUS00**

APPLICATION NO.

**09/976,858**

APPLICANT

**Kurt C. Gish, et al.**

FILING DATE

**October 12, 2001**

GROUP

**1642**

**	C11.	Majeed, et al., "Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998," <i>BJU Int.</i> 85(9):1058-62 (2000)
**	C12.	Nowroozi, et al., "The Current Status of Gene Therapy for Prostate Cancer," <i>Cancer Control</i> 5(6):522-31.
**	C13.	Panvichian, et al., "Hormonal and Chemotherapeutic Systemic Therapy for Metastatic Prostate Cancer," <i>Cancer Control</i> 3(6):493-500 (1996)
**	C14.	Rago, et al., "Management of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer," <i>Cancer Control</i> 5(6):513-21 (1998)
**	C15.	Nagabhushan, et al., "CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar," <i>Cancer Res.</i> 56(13):3042-6 (1996)
**	C16.	Agus, et al., "Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence," <i>J. Natl. Cancer Inst.</i> 91(21):1869-76 (1999)
**	C17.	Bubendorf, L., "Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays," <i>J. Natl. Cancer Inst.</i> 91(20):1758-64 (1999)
**	C18.	Smith, et al., "Paclitaxel in the treatment of hormone-refractory prostate cancer," <i>Semin Oncol.</i> 26 (1 Suppl 2):109-11 (1999)
**	C19.	Yang, et al., "Combining SSH and cDNA microarrays for rapid identification of differentially expressed genes," <i>Nucleic Acids Res.</i> 27(6):1517-1523 (1999)
**	C20.	Derisi, et al., "Use of cDNA microarray to analyse gene expression patterns in human cancer," <i>Nature Genetics</i> 14:457-60 (1996)
**	C21.	Welford, et al., "Detection of differentially expressed genes in primary tumor tissues using representational differences analysis coupled to microarray hybridization," <i>Nucleic Acids Res.</i> 26(12):3059-65 (1998)
**	C22.	Khan, et al., "Expression profiling in cancer using cDNA microarrays," <i>Electrophoresis</i> 20:223-9 (1999)
**	C23.	Ross, et al., "The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy," <i>Stem Cells</i> 16(6):413-28 (1998)
**	C24.	Maloney, et al., "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma," <i>Blood</i> 90(6):2188-95 (1997)
**	C25.	Leget, et al., "Use of rituximab, the new FDA-approved antibody," <i>Curr Opin Oncol.</i> 10(6):548-51 (1998)
**	C26.	Israeli, et al., "Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen," <i>Cancer Res.</i> 53(2):227-30 (1993)
**	C26.	Reiter, et al., "Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 95(4):1735-40 (1998)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

M: T, D, BWS

05/20/05



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)  <b>PTO FORM 1449</b>	ATTY. DOCKET NO.	APPLICATION NO.
	05882.0183.NPUS00	09/976,858
	APPLICANT	
	Kurt C. Gish, <i>et al.</i>	
	FILING DATE	GROUP
	October 12, 2001	1642

28

**	C27.	Hubert, <i>et al.</i> , "STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 96(25):14523-8 (1999)
**	C28.	Carter, <i>et al.</i> , "Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 93(2):749-53 (1996)
**	C29.	Sodee, <i>et al.</i> , "Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer," <i>Clin. Nucl. Med.</i> 21(10):759-67 (1996)
**	C30.	Gregorakis, <i>et al.</i> , "Prostate-specific membrane antigen: current and future utility," <i>Semin Urol. Oncol.</i> 16(1):2-12 (1998)
**	C31.	Liu, <i>et al.</i> , "Constitutive and antibody-induced internalization of prostate-specific membrane antigen," <i>Cancer Res.</i> 58(18):4055-60 (1998)
**	C32.	Murphy, <i>et al.</i> , "Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen," <i>J. Urol.</i> 160(6 Pt 2):2396-401 (1998)
**	C33.	Silver, <i>et al.</i> , "Prostate-specific membrane antigen expression in normal and malignant human tissue," <i>Clin. Cancer Res.</i> 3(1):81-5 (1997)
**	C34.	Liefers, <i>et al.</i> , "Micrometastases and Survival in Stage II Colorectal Cancer," <i>New England J. Med.</i> 339(4):223-8 (1998)
**	C35.	Gu, <i>et al.</i> , "Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer," <i>Oncogene</i> 19(10):1288-96 (2000)
**	C36	Nagase, <i>et al.</i> , "Prediction of the coding sequences of unidentified human genes XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro," <i>DNA Res.</i> 7(1):65-73 (2000)

M. T. DAVIS 05/20/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.